Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer

Fig. 1

Identification of differently methylated CpGs (DM-CpGs) in non-malignant prostate (N), primary prostate tumor (T), and bone metastasis (M) tissue samples. A, B PCA plots based on 121,944 promoter associated CpGs in the HumanMethylation EPIC arrays. A The colors represent patient treatment; no treatment/hormone naïve (orange), castrate-resistant prostate cancer (CRPC) (black), and short term androgen deprivation therapy (blue). Non-malignant (white) and primary tumor (grey) tissues are shown. B The same loading plot as in Fig. A with epithelial fractions shown. C DM-CpG sites between the primary tumor (T) and non-malignant (N) prostate tissue (n = 4360), between the N and metastasis (M) tissue (n = 14,875) and between the M and T tissue (n = 1183). The overlaps include DM-CpGs both in the same direction between comparisons (e.g. hyper-hyper) as well as DM-CpGs in different directions (e.g. hypo-hyper). The hyper- and hypomethylated CpGs are also separately shown. D Heatmap showing the 4360 DM-CpGs (identified in Fig. C) between T (n = 12) and N (n = 12). E Heatmap showing the 1183 DM-CpGs (identified in Fig. C) between M (n = 70) and T (n = 12)

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us